Sorry, you need to enable JavaScript to visit this website.

Skip to main content


Focus on Alzheimer’s Disease

Alzheimer’s Disease
Our Areas of Interest for Collaboration
Disease - Modifying ActivitySymptomatic Treatment of Cognitive Impairment and Neuropsychiatric ConditionsBiomarkers and Diagnostics
  • Agents in preclinical stage or later should have preclinical validated in vivo, proof-of-concept data
    • ApoE modulators Gamma secretase modulator Tau modulators
  • Novel agents with Phase 2 proof-of- concept in neuropsychiatric symptoms or neuropsychiatric symptoms with cognitive impairment that exhibit superior efficacy to standard of care (e.g., antipsychotics, acetylcholinesterase inhibitors) as monotherapy or adjunctive therapy with synergistic efficacy.
  • Examples include:
    - GABA-A alpha 5 inverse agonist
    - MGluR2 antagonist/NAM
  • Prognostic, diagnostic and disease progression biomarkers
  • Diagnostic imaging agents, including imaging of disease pathology (Abeta, tau), structural and functional MRI
  • Improved cerebrospinal fluid and blood biomarker assays
  • Novel animal models for target evaluation



Nerve fibers
Nerve fibers